NeoGenomics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
NeoGenomics, Inc. (NEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $96.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-17
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $96.00K, a 95.55% decline from fiscal 2024.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.16M, a 57.25% increase from fiscal 2023.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.37M, a 77.31% decline from fiscal 2022.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $6.05M, a 87.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $96.00K 10-K · filed 2026-02-17 | |
| 2024-12-31 | $2.16M 10-K · filed 2026-02-17 | |
| 2023-12-31 | $1.37M 10-K · filed 2026-02-17 | |
| 2022-12-31 | $6.05M 10-K · filed 2025-02-18 | $6.10M 10-K · filed 2023-02-24 |
| 2021-12-31 | $46.69M 10-K · filed 2024-02-20 | $46.70M 10-K · filed 2022-02-25 |
| 2020-12-31 | $68.60M 10-K · filed 2023-02-24 | |
| 2019-12-31 | $35.30M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $29.30M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $2.80M 10-K · filed 2020-02-28 | $2.77M 10-K · filed 2018-03-13 |
| 2016-12-31 | $15.00M 10-K · filed 2019-02-26 | $15.00M 10-K · filed 2017-03-14 |
| 2015-12-31 | $2.47M 10-K · filed 2018-03-13 | |
| 2014-12-31 | $8.88M 10-K · filed 2017-03-14 | |
| 2013-12-31 | $1.20M 10-K · filed 2016-04-18 | |
| 2012-12-31 | $264.00K 10-K · filed 2015-03-03 | |
| 2011-12-31 | $126.00K 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |